Related Experiment Video
Updated: Mar 23, 2026

Analysis of Cell Cycle Position in Mammalian Cells
Published on: January 21, 2012
NORE1A Regulates MDM2 Via β-TrCP
M Lee Schmidt1, Diego F Calvisi2, Geoffrey J Clark3
1Department of Pharmacology and Toxicology, James Graham Brown Cancer Center Molecular Targets Group, University of Louisville, Louisville, KY 40202, USA. lee.schmidt@louisville.edu.
Abstract:
Mouse Double Minute 2 Homolog (MDM2) is a key negative regulator of the master tumor suppressor p53. MDM2 regulates p53 on multiple levels, including acting as an ubiquitin ligase for the protein, thereby promoting its degradation by the proteasome. MDM2 is oncogenic and is frequently found to be over-expressed in human tumors, suggesting its dysregulation plays an important role in human cancers. We have recently found that the Ras effector and RASSF (Ras Association Domain Family) family member RASSF5/NORE1A enhances the levels of nuclear p53. We have also found that NORE1A (Novel Ras Effector 1A) binds the substrate recognition component of the SCF-ubiquitin ligase complex β-TrCP. Here, we now show that NORE1A regulates MDM2 protein levels by targeting it for ubiquitination by SCF-β-TrCP. We also show the suppression of NORE1A protein levels enhances MDM2 protein expression. Finally, we show that MDM2 can suppress the potent senescence phenotype induced by NORE1A over-expression. Thus, we identify a mechanism by which Ras/NORE1A can modulate p53 protein levels. As MDM2 has several important targets in addition to p53, this finding has broad implications for cancer biology in tumor cells that have lost expression of NORE1A due to promoter methylation.
Insights
Novel Ras Effector 1A (NORE1A) targets Mouse Double Minute 2 Homolog (MDM2) for degradation, impacting tumor suppressor p53 levels. Loss of NORE1A promotes MDM2 expression, with implications for cancer biology.
Area of Science:
- Molecular Biology
- Cancer Biology
- Cell Signaling
Background:
- Mouse Double Minute 2 Homolog (MDM2) is an oncogenic negative regulator of the tumor suppressor p53.
- MDM2 targets p53 for proteasomal degradation via its ubiquitin ligase activity.
- MDM2 overexpression is common in human cancers, indicating its role in tumorigenesis.
Purpose of the Study:
- To investigate the regulatory role of RASSF5/NORE1A in MDM2 protein levels.
- To elucidate the mechanism by which NORE1A influences MDM2 ubiquitination and degradation.
- To understand the functional consequences of the NORE1A-MDM2 interaction on p53 regulation and cellular phenotypes.
Main Methods:
- Co-immunoprecipitation assays to detect protein-protein interactions.
- Western blotting to assess protein levels and ubiquitination.
- Overexpression and knockdown studies to evaluate functional effects.
Main Results:
- RASSF5/NORE1A directly interacts with the SCF-β-TrCP ubiquitin ligase complex.
- NORE1A promotes MDM2 ubiquitination and subsequent degradation through SCF-β-TrCP.
- Suppression of NORE1A leads to increased MDM2 protein levels.
- MDM2 antagonizes the senescence-inducing effects of NORE1A overexpression.
Conclusions:
- NORE1A acts as a negative regulator of MDM2 protein stability.
- This mechanism provides a novel pathway for Ras/NORE1A to modulate p53 levels.
- Dysregulation of this pathway, particularly loss of NORE1A expression in tumors, has significant implications for cancer development and progression.
Related Concept Videos
Master Transcription Regulators
Abnormal Proliferation
Negative Regulator Molecules
MAPK Signaling Cascades
Regulation of Nuclear Protein Sorting
Nonsense-mediated mRNA Decay
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...

